CHELSEA MINERT: Open Payments
NPI 1730546359 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$620 in 36 payments from 12 companies in 2025. Trend: 2023 $922 · 2024 $713 · 2025 $620
Food & beverage: $620
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 14 | $154 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $87 |
| Vifor Pharma, Inc. | 3 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Calliditas Therapeutics US Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $43 |
| AKEBIA THERAPEUTICS INC | 1 | $28 |
| Travere Therapeutics, Inc. | 1 | $25 |
| SCPHARMACEUTICALS INC. | 1 | $22 |
Products named: Kerendia, JARDIANCE, Veltassa, VELPHORO, ACTHAR, TARPEYO, Vafseo, FUROSCIX.
Industry payments across NE — which companies pay providers there.
